AX-2026-042114
Tirzepatide · 60 mg declared · Guangzhou JEEP Biotechnology Co., Ltd. · lot JEEP-2602-J7978
- Report ID
- AX-2026-042114
- Compound
- Tirzepatide
- Compound class
- Incretin analogues and co-agonists
- Supplier
- JEEP — Guangzhou JEEP Biotechnology Co., Ltd.
- Batch / lot
- JEEP-2602-J7978
- Declared label claim
- 60mg
- Laboratory
- Nordanalyt Laboratories
- Assay date
- 15 Jun 2026
- Submitted
- 05 Jul 2026
- Quarter
- 2026-Q2
- Submitter
- ru.sobczak
- Sample provenance
- Buyer-sourced
Results
Measured against the index acceptance specification for the incretin analogues and co-agonists class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.
| Parameter | Method | Result | Unit | Index spec | |
|---|---|---|---|---|---|
| Purity | RP-HPLC, 35 min gradient, 214 nm | 98.83 | % area | ≥ 97.0 | PASS |
| Total impurities | RP-HPLC, sum of reported peaks | 1.17 | % area | ≤ 3.0 | PASS |
| Largest single impurity | RP-HPLC — Met(O) sulfoxide (+16 Da) | 0.72 | % area | ≤ 1.00 | PASS |
| Identity — theoretical monoisotopic mass | calculated from molecular formula | 4810.4103 | Da | — | NOT TESTED |
| Identity — observed monoisotopic mass | LC-MS, high resolution (ESI-TOF/QTOF) | 4810.4368 | Da | — | NOT TESTED |
| Mass accuracy | observed vs theoretical | +5.5 | ppm | ± 15 | PASS |
| Total peptide content | by difference from the gravimetric mass balance | 89.49 | %w/w | — | NOT TESTED |
| Target-compound content | total peptide content × purity | 88.44 | %w/w | — | NOT TESTED |
| Gross fill (as weighed) | five-place balance, under nitrogen | 69.38 | mg | 60 mg declared | NOT TESTED |
| Recovered target peptide | gross fill × target content | 61.360 | mg | 60 mg claim | NOT TESTED |
| Recovery against label claim | recovered ÷ claim | 102.3 | % | 90.0 – 110.0 | PASS |
| Water content | Karl Fischer, coulometric, duplicate | 4.17 | % | ≤ 8.0 | PASS |
| Counter-ion (TFA) | anion-exchange ion chromatography | 5.78 | % | ≤ 12.0 | PASS |
| Residual solvent + inorganic residue | estimated — see /methods/residual-solvents-q3c/ | 0.56 | % | — | NOT TESTED |
| Endotoxin | not ordered on this submission | not determined | — | ≤ 5.0 | NOT TESTED |
| Sterility | not ordered on this submission | not determined | — | no growth | NOT TESTED |
| Appearance | visual, diffuse light, black and white background | White lyophilised cake, intact | — | white to off-white intact cake | PASS |
| Reconstitution clarity | reconstituted per submitter procedure | Clear, colourless, no visible particulates | — | clear, no visible particulates | PASS |
| pH (reconstituted, 1 mg/mL) | potentiometric, two-point calibration | 3.05 | — | 2.5 – 8.0 | PASS |
| Retention time (observed) | RP-HPLC, 35 min gradient | 23.03 | min | 22.91 ± 0.45 (normalised) | PASS |
| Peak asymmetry (10 % height) | Ph. Eur. 2.2.46 | 0.98 | — | 0.80 – 1.50 | PASS |
| Plate count, main peak | N = 5.54 (t/w½)² | 70,910 | — | ≥ 20,000 | PASS |
| Resolution to nearest impurity | vs [D-Aib13]-diastereomer | 0.63 | — | no index criterion | REPORTED |
Chromatogram and peak integration
The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.
| # | Peak | RT | Area (µV·s) | % area | Δ mass (Da) |
|---|---|---|---|---|---|
| 1 | Tirzepatide — main peak | 23.03 | 4,803,444 | 98.83 | — |
| 2 | Met(O) sulfoxide (+16 Da) | 22.17 | 34,994 | 0.72 | +15.995 |
| 3 | des-Gly deletion (−57 Da) | 22.32 | 9,235 | 0.19 | -57.021 |
| 4 | truncated (3-39) | 21.30 | 5,346 | 0.11 | -222.112 |
| 5 | [D-Aib13]-diastereomer | 22.81 | 3,888 | 0.08 | 0.000 |
| 6 | des-Aib2 analogue | 22.62 | 3,402 | 0.07 | -85.053 |
| Closure check — purity + Σ impurities | 100.00 | CLOSES | |||
Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.
Mass spectrum and identity
Theoretical monoisotopic mass 4810.4103 Da, computed from C225H348N48O68. All ppm figures on this site are against monoisotopic values — see why that matters.
| Charge | Theoretical m/z | Observed m/z | Δ m/z | Rel. abundance (%) |
|---|---|---|---|---|
| 7+ | 688.2087 | 688.2125 | 0.0038 | 8.7 |
| 6+ | 802.7423 | 802.7467 | 0.0044 | 57.3 |
| 5+ | 963.0893 | 963.0946 | 0.0053 | 100.0 |
| 4+ | 1203.6099 | 1203.6165 | 0.0066 | 59.8 |
| 3+ | 1604.4774 | 1604.4862 | 0.0088 | 8.2 |
Gravimetric mass balance
Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.
| Component | Determination | %w/w of cake |
|---|---|---|
| Water | Karl Fischer | 4.17 |
| Counter-ion (TFA) | ion chromatography | 5.78 |
| Residual solvent + inorganic residue | estimated | 0.56 |
| Total peptide content | by difference | 89.49 |
| Total | 100.00 CLOSES | |
Supplier certificate, as declared
The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.
| Figure | Supplier COA | This report | Index note |
|---|---|---|---|
| Purity (% area) | 98.60 | 98.83 | divergence -0.26 pp vs batch median |
| Total impurities (% area) | not stated | 1.17 | |
| Largest single impurity (% area) | not stated | 0.72 | |
| Water (%) | not stated | 4.17 | |
| Counter-ion (%) | 4.6 | 5.78 | |
| Peptide content (%w/w) | 91.3 | 89.49 | |
| Endotoxin (EU/mg) | 0.49 | not determined | |
| Method stated on certificate | NO | — | no method section — the result cannot be reconciled against any other |
Provenance and caveats
Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.
- Sample provenance
- Buyer-sourced
- Evidentiary weight
- Strongest available evidence in this index.
- Chain of custody
- Retail purchase → third-party forwarder (23 d) → laboratory (courier, cold pack, 2 d) → assay.
- Assay date
- 15 Jun 2026
- Submitted to the index
- 05 Jul 2026
- Laboratory
- Nordanalyt Laboratories, Uppsala, Sweden
- Method basis
- 35 min gradient · high-resolution MS
- Verification status
- VERIFIED
Annotations
No annotations on this record. Annotations are short signed technical comments from index contributors; see how to contribute.
Related records
Same batch — lot JEEP-2602-J7978 n=15
| Report | Lot | Lab | Quarter | Purity % | Water % | Recovery % | Provenance | Flags | Result |
|---|---|---|---|---|---|---|---|---|---|
| AX-2026-042107 | JEEP-2602-J7978 | Nordanalyt | 2026-Q2 | 99.40 | 4.57 | — | Buyer-sourced | 0 | PASS |
| AX-2026-042108 | JEEP-2602-J7978 | Janoshik | 2026-Q2 | 98.86 | 4.29 | — | Buyer-sourced | 0 | PASS |
| AX-2026-042109 | JEEP-2602-J7978 | PeptideMeter | 2026-Q2 | 98.36 | 4.90 | 98.1 | Buyer-sourced | 0 | PASS |
| AX-2026-042110 | JEEP-2602-J7978 | Janoshik | 2026-Q2 | 98.78 | 4.26 | — | Buyer-sourced | 0 | PASS |
| AX-2026-042111 | JEEP-2602-J7978 | PeptideMeter | 2026-Q2 | 98.67 | 4.80 | — | Buyer-sourced | 0 | PASS |
| AX-2026-042112 | JEEP-2602-J7978 | Janoshik | 2026-Q2 | 99.15 | 4.37 | — | Buyer-sourced | 0 | PASS |
| AX-2026-042113 | JEEP-2602-J7978 | VendorInvestigate | 2026-Q2 | 98.56 | 4.81 | — | Buyer-sourced | 0 | PASS |
| AX-2026-042115 | JEEP-2602-J7978 | Medutest | 2026-Q2 | 99.14 | 4.85 | 97.7 | Buyer-sourced | 0 | PASS |
| AX-2026-042116 | JEEP-2602-J7978 | Nordanalyt | 2026-Q2 | 99.08 | 5.04 | 105.7 | Buyer-sourced | 0 | PASS |
| AX-2026-042117 | JEEP-2602-J7978 | Janoshik | 2026-Q2 | 98.92 | 5.32 | 99.8 | Buyer-sourced | 0 | PASS |
| AX-2026-042118 | JEEP-2602-J7978 | Medutest | 2026-Q2 | 99.12 | 4.38 | 88.7 | Buyer-sourced | 1 | MARGINAL |
| AX-2026-042119 | JEEP-2602-J7978 | Janoshik | 2026-Q2 | 98.59 | 4.12 | 98.4 | Buyer-sourced | 0 | PASS |
| AX-2026-042120 | JEEP-2602-J7978 | Nordanalyt | 2026-Q2 | 98.86 | 4.68 | — | Buyer-sourced | 0 | PASS |
| AX-2026-042121 | JEEP-2602-J7978 | Nordanalyt | 2026-Q2 | 98.56 | 4.41 | — | Buyer-sourced | 0 | PASS |
Cross-sections
| Report | Supplier | Lot | Lab | Quarter | Purity % | Water % | Recovery % | Provenance | Flags | Result |
|---|---|---|---|---|---|---|---|---|---|---|
| AX-2026-043288 | CPC | CPC-2607-L1516 | Janoshik | 2026-Q3 | 96.89 | 5.11 | 101.1 | Laboratory-retained | 0 | FAIL |
| AX-2026-041610 | FGP | FGP-2603-L7753 | Janoshik | 2026-Q3 | 98.81 | 2.45 | 101.0 | Buyer-sourced | 0 | PASS |
| AX-2026-041974 | AMB | AMB-2603-C5112 | Nordanalyt | 2026-Q3 | 98.20 | 3.41 | — | Buyer-sourced | 0 | PASS |
| AX-2026-041975 | AMB | AMB-2603-C5112 | Medutest | 2026-Q3 | 97.88 | 3.45 | 106.9 | Laboratory-retained | 0 | PASS |
| AX-2026-041609 | FGP | FGP-2603-L7753 | Janoshik | 2026-Q3 | 98.52 | 2.00 | 98.0 | Buyer-sourced | 0 | PASS |
| AX-2026-041978 | AMB | AMB-2603-C5112 | Janoshik | 2026-Q3 | 97.94 | 3.57 | 103.0 | Buyer-sourced | 0 | PASS |
| AX-2026-041982 | AMB | AMB-2603-C5112 | Janoshik | 2026-Q3 | 97.60 | 4.46 | — | Buyer-sourced | 0 | PASS |
| AX-2026-043286 | CPC | CPC-2607-L1516 | Kestrel | 2026-Q3 | 98.20 | 4.56 | — | Buyer-sourced | 0 | PASS |
| Report | Compound | Lot | Lab | Quarter | Purity % | Water % | Recovery % | Provenance | Flags | Result |
|---|---|---|---|---|---|---|---|---|---|---|
| AX-2026-042177 | Hexarelin | JEEP-2608-Y9547 | Janoshik | 2026-Q3 | 99.90 | 3.42 | — | Buyer-sourced | 0 | PASS |
| AX-2026-042162 | Semaglutide | JEEP-2607-X9091 | Janoshik | 2026-Q3 | 98.98 | 3.46 | — | Laboratory-retained | 1 | MARGINAL |
| AX-2026-042127 | TB-500 | JEEP-2602-V8614 | Medutest | 2026-Q3 | 99.68 | 3.55 | — | Buyer-sourced | 1 | FAIL |
| AX-2026-042123 | TB-500 | JEEP-2602-V8614 | PeptideMeter | 2026-Q3 | 99.93 | 3.80 | — | Buyer-sourced | 0 | PASS |
| AX-2026-042124 | TB-500 | JEEP-2602-V8614 | PeptideMeter | 2026-Q3 | 99.91 | 3.37 | 104.9 | Buyer-sourced | 0 | PASS |
| AX-2026-042178 | Hexarelin | JEEP-2608-Y9547 | VendorInvestigate | 2026-Q3 | 99.68 | 4.03 | — | Buyer-sourced | 0 | PASS |
| AX-2026-042163 | Semaglutide | JEEP-2607-X9091 | Nordanalyt | 2026-Q3 | 99.46 | 4.52 | — | Buyer-sourced | 1 | MARGINAL |
| AX-2026-042122 | TB-500 | JEEP-2602-V8614 | PeptideMeter | 2026-Q3 | 99.60 | 3.58 | 97.0 | Buyer-sourced | 0 | PASS |